Congress shields radiation oncology from Medicare cost controls, raising taxpayer burden

What it does

This bill creates a new Medicare payment system for radiation oncology services that bundles payments per treatment episode rather than per individual service. It exempts this new program from budget-neutrality requirements (meaning savings don't trigger automatic payment cuts elsewhere), and it creates a legal safe harbor allowing radiation therapy providers to offer free or discounted transportation to patients without violating anti-kickback rules.

Why we flagged it

The bill's core mechanism is a bundled payment model for radiation oncology—a legitimate payment reform. However, the budget-neutrality exemption is a fiscal carve-out that shields the program from the normal cost-control mechanism applied to other Medicare innovations, effectively subsidizing the program at taxpayer expense.

What the text implies

• The budget-neutrality exemption (Section 5) means savings from the ROCR Program do not reduce other Medicare payment rates. This is a hidden fiscal cost: the program's efficiency gains are not recycled into the broader Medicare system, effectively creating a permanent subsidy for radiation oncology relative to other cancer treatments.
• The transportation add-on payment ($500–$510 per patient per episode) is conditioned on reporting ICD-10 code Z59.82 (transportation insecurity), but the bill does not mandate that providers screen for or report this code. Uptake and equity of the benefit depend entirely on provider discretion and patient disclosure, creating a hidden access disparity.
• The bill requires radiation therapy providers to participate in the ROCR Program (mandatory participation, Section 3(6)(1)), but exempts those in state-based CMMI models and allows hardship exemptions. This creates a two-tier system where some providers remain outside the bundled payment model, potentially fragmenting care and complicating beneficiary navigation.
• The accreditation requirement (Section 3(7)(2)) mandates compliance with standards set by the American College of Radiology, American College of Radiation Oncology, or American Society for Radiation Oncology. These are private professional organizations whose standards are not subject to public notice-and-comment rulemaking, creating a hidden delegation of regulatory authority to private entities.
• The 12-year exclusion of advanced modalities (brachytherapy, proton therapy, therapeutic radiopharmaceuticals) from the bundled payment model (Section 3(3)(2)(B)) protects the base rates from cost pressure but may delay patient access to newer, potentially more effective treatments by locking them out of the stable payment structure.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill offers concrete benefits to cancer patients—stable, predictable payments that may improve access to radiation therapy, plus a $500+ annual add-on payment to support transportation for patients with transportation insecurity. However, the budget-neutrality exemption means the program's cost reductions will not offset other Medicare spending, shifting the fiscal burden to taxpayers or other beneficiaries. The transportation safe harbor is genuinely beneficial but narrowly scoped.

Who stands to gain

• radiation therapy providers and suppliers (hospital outpatient departments, physician groups, freest
• radiation oncology equipment manufacturers (through stable, predictable payment environment)
• professional accreditation organizations (American College of Radiology, American College of Radiati

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Secretary of Health and Human Services, American College of Radiology, American College of Radiation Oncology, American Society for Radiation Oncology, Comptroller General of the US, Medicare beneficiaries (Part B, non-Advantage), radiation therapy providers, radiation therapy suppliers, AIG, FBK, FMAO — and 2 more

Where it stands

6 cosponsors: 4 Republicans, 2 Democrats.

• Mar 13, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 13, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

10 lobbying clients named this bill on 17 disclosure filings across 4 quarters, Sep 2025 to Jun 2026. Those filings disclosed $3,946,582 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 91% of bills with at least one filing.

Thom Tillis, the sponsor, reported $973,475 in PAC receipts in the 2026 cycle.

• Boston Scientific Corporation — $1,212,000 on 2 filings
• Siemens Medical Solutions Usa, Inc — $860,000 on 1 filing
• Trinity Health — $720,000 on 3 filings
• Association for Clinical Oncology — $480,000 on 1 filing
• American Society for Radiation Oncology — $384,582 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.